TY - JOUR
T1 - Atrial Fibrillation
T2 - Unanswered Questions and Future Directions
AU - Reddy, Vivek Y.
N1 - Funding Information:
This work was supported in part by the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke. Dr. Reddy has received grant support or served as a consultant to Biosense-Webster, Inc., CardioFocus, Inc., Cryocath Technologies Inc., GE Medical Systems, Inc., Hansen Medical, Inc., Philips Medical Systems, Inc., ProRhythm, Inc., St. Jude Medical, Inc., and Stereotaxis, Inc.
PY - 2008/1
Y1 - 2008/1
N2 - Just more than a decade ago, Haissaguerre and colleagues provided the seminal demonstration of the role of pulmonary vein triggers in the pathogenesis of atrial fibrillation (AF) and the potential therapeutic role of catheter ablation to treat patients who have paroxysmal AF. This initial observation ushered in the modern era of catheter ablation to treat patients who have AF, and tremendous progress has been made in understanding its pathogenesis and the catheter approaches to treating this rhythm. Although the current state of AF catheter ablation is well described earlier in this issue, this article reflects on some of the major unanswered questions about AF management, and the future technological and investigational directions being explored in the nonpharmacologic management of AF.
AB - Just more than a decade ago, Haissaguerre and colleagues provided the seminal demonstration of the role of pulmonary vein triggers in the pathogenesis of atrial fibrillation (AF) and the potential therapeutic role of catheter ablation to treat patients who have paroxysmal AF. This initial observation ushered in the modern era of catheter ablation to treat patients who have AF, and tremendous progress has been made in understanding its pathogenesis and the catheter approaches to treating this rhythm. Although the current state of AF catheter ablation is well described earlier in this issue, this article reflects on some of the major unanswered questions about AF management, and the future technological and investigational directions being explored in the nonpharmacologic management of AF.
UR - http://www.scopus.com/inward/record.url?scp=36448971606&partnerID=8YFLogxK
U2 - 10.1016/j.mcna.2007.09.008
DO - 10.1016/j.mcna.2007.09.008
M3 - Review article
C2 - 18061007
AN - SCOPUS:36448971606
SN - 0025-7125
VL - 92
SP - 237
EP - 258
JO - Medical Clinics of North America
JF - Medical Clinics of North America
IS - 1
ER -